Clinical trial start times are influenced more by internal operations than regulatory reviews, according to new industry analysis. The study highlights that how pharmaceutical companies organize their teams and manage trial sites plays a key role in how quickly studies begin. Regulatory approval periods remain consistent across the industry, but the speed at which trials launch varies widely. Companies using dedicated trial units and streamlined internal processes report faster enrollment of first patients. These findings suggest that improving internal coordination could help shorten the time it takes to start new clinical studies. The research underscores the importance of operational efficiency in accelerating drug development timelines.